2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19
Open Access
- 7 October 2021
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (1), 34-40
- https://doi.org/10.1136/annrheumdis-2021-221366
Abstract
Objectives To update the EULAR points to consider (PtCs) on the use of immunomodulatory therapies in COVID-19. Methods According to the EULAR standardised operating procedures, a systematic literature review up to 14 July 2021 was conducted and followed by a consensus meeting of an international multidisciplinary task force. The new statements were consolidated by formal voting. Results We updated 2 overarching principles and 12 PtC. Evidence was only available in moderate to severe and critical patients. Glucocorticoids alone or in combination with tocilizumab are beneficial in COVID-19 cases requiring oxygen therapy and in critical COVID-19. Use of Janus kinase inhibitors (baricitinib and tofacitinib) is promising in the same populations of severe and critical COVID-19. Anti-SARS-CoV-2 monoclonal antibodies and convalescent plasma may find application in early phases of the disease and in selected subgroups of immunosuppressed patients. There was insufficient robust evidence for the efficacy of other immunomodulators with further work being needed in relation to biomarker-based stratification for IL-1 therapy Conclusions Growing evidence supports incremental efficacy of glucocorticoids alone or combined with tocilizumab/Janus kinase inhibitors in moderate to severe and critical COVID-19. Ongoing studies may unmask the potential application of other therapeutic approaches. Involvement of rheumatologists, as systemic inflammatory diseases experts, should be encouraged in clinical trials of immunomodulatory therapy in COVID-19.Funding Information
- European Alliance of Associations in Rheumatology (CLI122)
This publication has 41 references indexed in Scilit:
- Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator TrialAnnals of the American Thoracic Society, 2021
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19The New England Journal of Medicine, 2021
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19The New England Journal of Medicine, 2021
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19JAMA, 2021
- Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trialRMD Open, 2021
- Merging shuttle reactions and paired electrolysis for reversible vicinal dihalogenationsScience, 2021
- Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trialThe Lancet Respiratory Medicine, 2021
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19The New England Journal of Medicine, 2021
- 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendationsAnnals Of The Rheumatic Diseases, 2014
- Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham Heart StudyAnnals Of The Rheumatic Diseases, 2013